Biogen Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value and what the price assumes
Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.
Starts at revenue growth over the last three years, -0.9% a year (statements).
US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).
Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.
Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.
Debt less cash at the end of FY2025 (statements); negative means more cash than debt.
What today's price assumes
A market value of $37.5 B means free cash flow growing 7.7% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.
Revenue grew -0.9% a year over the last three years.
Against the market value, for other rates
Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.
| Discount rate ↓ / growth → | -5.94% | -3.44% | -0.94% | 1.56% | 4.06% |
|---|---|---|---|---|---|
| 7.92% | -56% | -45% | -31% | -14% | +6% |
| 8.92% | -63% | -54% | -43% | -29% | -12% |
| 9.92% | -68% | -60% | -51% | -39% | -26% |
| 10.92% | -72% | -65% | -57% | -48% | -36% |
| 11.92% | -75% | -69% | -62% | -54% | -44% |
On one scale
Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.
Your own DCF model
A full discounted-cash-flow model of Biogen Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Pharmaceutical
Multiples of its companies with a market value at most 60 days old, times Biogen Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Biogen Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| P/E | 18.4× / 38.6× / 50.3× | 108.0× | net income $1.3 B | $23.7 B to $65.1 B | 53 |
| Price to sales | 1.5× / 3.5× / 6.7× | 3.6× | revenue $9.9 B | $15.0 B to $66.3 B | 68 |
| Price to book | 2.1× / 4.1× / 8.2× | 2.1× | book equity $18.3 B | $38.9 B to $149.3 B | 62 |
Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.
Against its own history
Biogen Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
P/E
45.0×Now above its median of 14.3×, in the top quarter of its range; range 6.4× to 45.0× over 30 months.
Price to sales
3.7×Now above its median of 2.6×, in the top quarter of its range; range 1.8× to 5.5× over 30 months.
Price to book
2.1×Now above its median of 1.6×, in the top quarter of its range; range 1.1× to 5.7× over 30 months.
as of Oct 23, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 23, 2026.
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $9.9 B | $1.3 B | $2.2 B | $154 M | $2.1 B | $3.3 B | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $9.7 B | $1.6 B | $2.9 B | $154 M | $2.7 B | $2.2 B | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $9.8 B | $1.2 B | $1.5 B | $277 M | $1.3 B | $5.7 B | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $10.2 B | $3.0 B | $1.4 B | $240 M | $1.1 B | $2.9 B | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $11.0 B | $1.6 B | $3.6 B | $258 M | $3.4 B | $4.0 B | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $13.4 B | $4.0 B | $4.2 B | $425 M | $3.8 B | $6.1 B | SEC annual report (10-K, 20-F) |
Each figure as filed; the full statements with every line and its filing are on the company page. Market value $37.5 B on Oct 23, 2026.
How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.